Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 4D Molecular Therapeutics, Inc.FDMT · Entity 2419 | Chief Legal Officer | September 16, 2026 | September 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
4D Molecular Therapeutics, Inc.
Report date September 16, 2026 · Filed September 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,617 |
Ending reported balance
After 2026-09-16 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-16 · Exercise / conversion · Acquired 1,635 · Balance 10,252 Row 2 · 2026-09-16 · Sale · Disposed 1,635 · Balance 8,617 F1: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 13, 2026. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.14 · Expires 2035-03-05 | Direct | 58,066 |
Reported balance
After 2026-09-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-16 · Exercise / conversion · Disposed 1,635 · Balance 58,066 F2: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 13, 2026.
F2: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2024 Filed Jul 3, 2024 21:11 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionStock Option (Right To Buy) · Derivative | 2,916 | $0.00 Strike: $8.04 | $0.00 |
DisclosureSEC source: 0000950170-24-081626 · ownership.xml · derivative · entry 5 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,752 Underlying: Common Stock · 2,916 shares Expires 2032-08-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. F4 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of September 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 21:11 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionStock Option (Right To Buy) · Derivative | 1,332 | $0.00 Strike: $6.49 | $0.00 |
DisclosureSEC source: 0000950170-24-081626 · ownership.xml · derivative · entry 4 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,879 Underlying: Common Stock · 1,332 shares Expires 2032-06-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. F3 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 21:11 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 4,248 | $21.36 | $90,757.67 |
DisclosureSEC source: 0000950170-24-081626 · ownership.xml · nonDerivative · entry 3 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,737 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. F2 · price: The transaction was executed in multiple trades in prices ranging from $21.01 to $21.74, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 21:11 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionCommon Stock | 2,916 | $8.04 | $23,444.64 |
DisclosureSEC source: 0000950170-24-081626 · ownership.xml · nonDerivative · entry 2 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,985 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 21:11 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionCommon Stock | 1,332 | $6.49 | $8,644.68 |
DisclosureSEC source: 0000950170-24-081626 · ownership.xml · nonDerivative · entry 1 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,069 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. Read SEC document |
| June 17, 2024 Filed Jun 20, 2024 20:59 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionStock Option (Right To Buy) · Derivative | 1,250 | $0.00 Strike: $8.04 | $0.00 |
DisclosureSEC source: 0000950170-24-075692 · ownership.xml · derivative · entry 5 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,668 Underlying: Common Stock · 1,250 shares Expires 2032-08-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. F4 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of September 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| June 17, 2024 Filed Jun 20, 2024 20:59 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionStock Option (Right To Buy) · Derivative | 500 | $0.00 Strike: $6.49 | $0.00 |
DisclosureSEC source: 0000950170-24-075692 · ownership.xml · derivative · entry 4 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,211 Underlying: Common Stock · 500 shares Expires 2032-06-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. F3 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| June 17, 2024 Filed Jun 20, 2024 20:59 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 1,750 | $23.71 | $41,493.55 |
DisclosureSEC source: 0000950170-24-075692 · ownership.xml · nonDerivative · entry 3 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,737 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. F2 · price: The transaction was executed in multiple trades in prices ranging from $23.45 to $24.44, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| June 17, 2024 Filed Jun 20, 2024 20:59 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionCommon Stock | 1,250 | $8.04 | $10,050.00 |
DisclosureSEC source: 0000950170-24-075692 · ownership.xml · nonDerivative · entry 2 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,487 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. Read SEC document |
| June 17, 2024 Filed Jun 20, 2024 20:59 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionCommon Stock | 500 | $6.49 | $3,245.00 |
DisclosureSEC source: 0000950170-24-075692 · ownership.xml · nonDerivative · entry 1 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,237 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. Read SEC document |
| May 16, 2024 Filed May 21, 2024 00:35 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionStock Option (Right To Buy) · Derivative | 1,250 | $0.00 Strike: $8.04 | $0.00 |
DisclosureSEC source: 0000950170-24-062637 · ownership.xml · derivative · entry 6 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,918 Underlying: Common Stock · 1,250 shares Expires 2032-08-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. F5 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of September 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| May 16, 2024 Filed May 21, 2024 00:35 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionStock Option (Right To Buy) · Derivative | 500 | $0.00 Strike: $6.49 | $0.00 |
DisclosureSEC source: 0000950170-24-062637 · ownership.xml · derivative · entry 5 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,711 Underlying: Common Stock · 500 shares Expires 2032-06-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. F4 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| May 16, 2024 Filed May 21, 2024 00:35 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 467 | $25.75 | $12,027.26 |
DisclosureSEC source: 0000950170-24-062637 · ownership.xml · nonDerivative · entry 4 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,737 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. F3 · price: The transaction was executed in multiple trades in prices ranging from $25.67 to $25.92, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| May 16, 2024 Filed May 21, 2024 00:35 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 1,283 | $25.34 | $32,513.79 |
DisclosureSEC source: 0000950170-24-062637 · ownership.xml · nonDerivative · entry 3 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,204 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. F2 · price: The transaction was executed in multiple trades in prices ranging from $24.67 to $25.65, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.. Read SEC document |
| May 16, 2024 Filed May 21, 2024 00:35 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionCommon Stock | 1,250 | $8.04 | $10,050.00 |
DisclosureSEC source: 0000950170-24-062637 · ownership.xml · nonDerivative · entry 2 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,487 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. Read SEC document |
| May 16, 2024 Filed May 21, 2024 00:35 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionCommon Stock | 500 | $6.49 | $3,245.00 |
DisclosureSEC source: 0000950170-24-062637 · ownership.xml · nonDerivative · entry 1 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,237 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. Read SEC document |
| April 16, 2024 Filed Apr 19, 2024 00:48 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionStock Option (Right To Buy) · Derivative | 1,250 | $0.00 Strike: $8.04 | $0.00 |
DisclosureSEC source: 0000950170-24-045702 · ownership.xml · derivative · entry 5 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,168 Underlying: Common Stock · 1,250 shares Expires 2032-08-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. F3 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of September 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| April 16, 2024 Filed Apr 19, 2024 00:48 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionStock Option (Right To Buy) · Derivative | 500 | $0.00 Strike: $6.49 | $0.00 |
DisclosureSEC source: 0000950170-24-045702 · ownership.xml · derivative · entry 4 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,211 Underlying: Common Stock · 500 shares Expires 2032-06-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. F2 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| April 16, 2024 Filed Apr 19, 2024 00:48 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 1,750 | $25.74 | $45,045.00 |
DisclosureSEC source: 0000950170-24-045702 · ownership.xml · nonDerivative · entry 3 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,737 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. Read SEC document |
| April 16, 2024 Filed Apr 19, 2024 00:48 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionCommon Stock | 1,250 | $8.04 | $10,050.00 |
DisclosureSEC source: 0000950170-24-045702 · ownership.xml · nonDerivative · entry 2 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,487 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. Read SEC document |
| April 16, 2024 Filed Apr 19, 2024 00:48 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionCommon Stock | 500 | $6.49 | $3,245.00 |
DisclosureSEC source: 0000950170-24-045702 · ownership.xml · nonDerivative · entry 1 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,237 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 23:18 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionStock Option (Right To Buy) · Derivative | 1,909 | $0.00 Strike: $20.24 | $0.00 |
DisclosureSEC source: 0000950170-24-041418 · ownership.xml · derivative · entry 9 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,182 Underlying: Common Stock · 1,909 shares Expires 2033-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. F5 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of February 10, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 23:18 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionStock Option (Right To Buy) · Derivative | 1,996 | $0.00 Strike: $15.78 | $0.00 |
DisclosureSEC source: 0000950170-24-041418 · ownership.xml · derivative · entry 8 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,008 Underlying: Common Stock · 1,996 shares Expires 2032-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. F4 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 23:18 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionStock Option (Right To Buy) · Derivative | 2,916 | $0.00 Strike: $8.04 | $0.00 |
DisclosureSEC source: 0000950170-24-041418 · ownership.xml · derivative · entry 7 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,418 Underlying: Common Stock · 2,916 shares Expires 2032-08-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. F3 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of September 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 23:18 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionStock Option (Right To Buy) · Derivative | 1,332 | $0.00 Strike: $6.49 | $0.00 |
DisclosureSEC source: 0000950170-24-041418 · ownership.xml · derivative · entry 6 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,711 Underlying: Common Stock · 1,332 shares Expires 2032-06-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. F2 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 23:18 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 8,153 | $31.78 | $259,102.34 |
DisclosureSEC source: 0000950170-24-041418 · ownership.xml · nonDerivative · entry 5 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,737 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 23:18 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionCommon Stock | 1,909 | $20.24 | $38,638.16 |
DisclosureSEC source: 0000950170-24-041418 · ownership.xml · nonDerivative · entry 4 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,890 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 23:18 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionCommon Stock | 1,996 | $15.78 | $31,496.88 |
DisclosureSEC source: 0000950170-24-041418 · ownership.xml · nonDerivative · entry 3 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,981 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 23:18 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionCommon Stock | 2,916 | $8.04 | $23,444.64 |
DisclosureSEC source: 0000950170-24-041418 · ownership.xml · nonDerivative · entry 2 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,985 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 23:18 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionCommon Stock | 1,332 | $6.49 | $8,644.68 |
DisclosureSEC source: 0000950170-24-041418 · ownership.xml · nonDerivative · entry 1 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,069 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. Read SEC document |
| March 27, 2024 Filed Mar 29, 2024 20:52 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionStock Option (Right To Buy) · Derivative | 1,491 | $0.00 Strike: $25.98 | $0.00 |
DisclosureSEC source: 0000950170-24-038731 · ownership.xml · derivative · entry 5 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,167 Underlying: Common Stock · 1,491 shares Expires 2031-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. F3 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from October 1, 2021 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest in thirty-six (36) successive and equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| March 27, 2024 Filed Mar 29, 2024 20:52 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionStock Option (Right To Buy) · Derivative | 4,342 | $0.00 Strike: $25.98 | $0.00 |
DisclosureSEC source: 0000950170-24-038731 · ownership.xml · derivative · entry 4 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,658 Underlying: Common Stock · 4,342 shares Expires 2031-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. F3 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from October 1, 2021 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest in thirty-six (36) successive and equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| March 27, 2024 Filed Mar 29, 2024 20:52 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 5,833 | $35.04 | $204,410.49 |
DisclosureSEC source: 0000950170-24-038731 · ownership.xml · nonDerivative · entry 3 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,737 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. F2 · price: The transaction was executed in multiple trades in prices ranging from $35.00 to $35.20, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| March 27, 2024 Filed Mar 29, 2024 20:52 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionCommon Stock | 1,491 | $25.98 | $38,736.18 |
DisclosureSEC source: 0000950170-24-038731 · ownership.xml · nonDerivative · entry 2 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,570 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. Read SEC document |
| March 27, 2024 Filed Mar 29, 2024 20:52 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionCommon Stock | 4,342 | $25.98 | $112,805.16 |
DisclosureSEC source: 0000950170-24-038731 · ownership.xml · nonDerivative · entry 1 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,079 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 20:40 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionStock Option (Right To Buy) · Derivative | 1,250 | $0.00 Strike: $8.04 | $0.00 |
DisclosureSEC source: 0000950170-24-034227 · ownership.xml · derivative · entry 5 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,334 Underlying: Common Stock · 1,250 shares Expires 2032-08-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. F3 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of September 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 20:40 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionStock Option (Right To Buy) · Derivative | 500 | $0.00 Strike: $6.49 | $0.00 |
DisclosureSEC source: 0000950170-24-034227 · ownership.xml · derivative · entry 4 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,043 Underlying: Common Stock · 500 shares Expires 2032-06-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. F2 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 20:40 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 1,750 | $31.27 | $54,722.50 |
DisclosureSEC source: 0000950170-24-034227 · ownership.xml · nonDerivative · entry 3 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,737 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 20:40 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionCommon Stock | 1,250 | $8.04 | $10,050.00 |
DisclosureSEC source: 0000950170-24-034227 · ownership.xml · nonDerivative · entry 2 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,487 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 20:40 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionCommon Stock | 500 | $6.49 | $3,245.00 |
DisclosureSEC source: 0000950170-24-034227 · ownership.xml · nonDerivative · entry 1 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,237 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 23:01 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionStock Option (Right To Buy) · Derivative | 1,909 | $0.00 Strike: $20.24 | $0.00 |
DisclosureSEC source: 0000950170-24-023330 · ownership.xml · derivative · entry 3 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,091 Underlying: Common Stock · 1,909 shares Expires 2032-06-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. F2 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of February 10, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 23:01 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 1,909 | $30.00 | $57,270.00 |
DisclosureSEC source: 0000950170-24-023330 · ownership.xml · nonDerivative · entry 2 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,737 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 23:01 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionCommon Stock | 1,909 | $20.24 | $38,638.16 |
DisclosureSEC source: 0000950170-24-023330 · ownership.xml · nonDerivative · entry 1 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,646 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 22:41 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionStock Option (Right To Buy) · Derivative | 1,250 | $0.00 Strike: $8.04 | $0.00 |
DisclosureSEC source: 0000950170-24-018155 · ownership.xml · derivative · entry 5 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,584 Underlying: Common Stock · 1,250 shares Expires 2032-08-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. F3 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of September 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 22:41 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionStock Option (Right To Buy) · Derivative | 500 | $0.00 Strike: $6.49 | $0.00 |
DisclosureSEC source: 0000950170-24-018155 · ownership.xml · derivative · entry 4 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,543 Underlying: Common Stock · 500 shares Expires 2032-06-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. F2 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 22:41 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 1,750 | $27.67 | $48,422.50 |
DisclosureSEC source: 0000950170-24-018155 · ownership.xml · nonDerivative · entry 3 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,737 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 22:41 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionCommon Stock | 1,250 | $8.04 | $10,050.00 |
DisclosureSEC source: 0000950170-24-018155 · ownership.xml · nonDerivative · entry 2 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,487 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 22:41 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionCommon Stock | 500 | $6.49 | $3,245.00 |
DisclosureSEC source: 0000950170-24-018155 · ownership.xml · nonDerivative · entry 1 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,237 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. Read SEC document |
| February 08, 2024 Filed Feb 13, 2024 02:04 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,996 | $0.00 Strike: $15.78 | $0.00 |
DisclosureSEC source: 0000950170-24-014119 · ownership.xml · derivative · entry 9 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,004 Underlying: Common Stock · 1,996 shares Expires 2032-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. F4 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| February 08, 2024 Filed Feb 13, 2024 02:04 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,916 | $0.00 Strike: $8.04 | $0.00 |
DisclosureSEC source: 0000950170-24-014119 · ownership.xml · derivative · entry 8 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,834 Underlying: Common Stock · 2,916 shares Expires 2032-08-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. F3 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of September 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.